Loading...
XSHE300194
Market cap681mUSD
Jan 10, Last price  
4.20CNY
1D
-3.67%
1Q
-6.25%
Jan 2017
-52.09%
IPO
-38.93%
Name

Fuan Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300194 chart
P/E
21.55
P/S
1.89
EPS
0.19
Div Yield, %
1.88%
Shrs. gr., 5y
0.34%
Rev. gr., 5y
-0.16%
Revenues
2.65b
+9.33%
93,440,606198,457,058324,528,285464,010,492358,548,287420,017,314357,779,550448,569,652708,096,0421,297,016,9102,090,806,8492,669,296,0822,780,740,6472,368,343,2962,453,144,9202,421,742,2922,647,752,954
Net income
232m
+13.32%
5,364,89245,698,95390,670,604123,136,91595,233,59688,505,12038,367,91145,707,27364,899,360221,958,231284,814,6640292,829,529209,369,5310204,607,567231,869,165
CFO
329m
-3.10%
18,916,52349,226,87362,747,733105,743,38064,851,07662,766,74189,610,1660161,026,698374,162,616453,370,240267,675,482295,627,587162,552,887257,128,839339,498,850328,978,126
Dividend
Jun 04, 20240.05 CNY/sh
Earnings
May 23, 2025

Profile

Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells pharmaceutical intermediates, bulk drugs, and formulations in the People's Republic of China. It offers APIs and intermediates, as well as formulations, such as anti-infective, cardiovascular, digestive, leaflet, and other products. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and changed its name to Fuan Pharmaceutical (Group) Co., Ltd. in August 2013. Fuan Pharmaceutical (Group) Co., Ltd. was founded in 2004 and is headquartered in Chongqing, the People's Republic of China.
URL
https://www.fapharm.com/
IPO date
Mar 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,647,753
9.33%
2,421,742
-1.28%
Cost of revenue
2,203,951
2,093,894
Unusual Expense (Income)
NOPBT
443,802
327,848
NOPBT Margin
16.76%
13.54%
Operating Taxes
55,949
Tax Rate
12.61%
NOPAT
387,853
327,848
Net income
231,869
13.32%
204,608
 
Dividends
(93,982)
Dividend yield
1.76%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
349,108
409,439
Long-term debt
490,271
305,818
Deferred revenue
92,356
98,064
Other long-term liabilities
10
177,275
Net debt
(1,335,451)
(1,045,460)
Cash flow
Cash from operating activities
328,978
339,499
CAPEX
(215,680)
Cash from investing activities
(93,622)
Cash from financing activities
46,254
FCF
360,056
169,019
Balance
Cash
996,889
703,744
Long term investments
1,177,941
1,056,973
Excess cash
2,042,442
1,639,630
Stockholders' equity
1,830,481
1,726,826
Invested Capital
3,248,422
3,256,370
ROIC
11.93%
9.89%
ROCE
8.65%
6.61%
EV
Common stock shares outstanding
1,220,364
1,189,712
Price
4.38
21.67%
3.60
-29.69%
Market cap
5,345,194
24.80%
4,282,965
-29.69%
EV
4,013,663
3,238,884
EBITDA
652,871
512,280
EV/EBITDA
6.15
6.32
Interest
30,392
26,938
Interest/NOPBT
6.85%
8.22%